Cancer Research Landon Prizes for Basic and Translational Cancer Research AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suzuki, C.
Right arrow Articles by Nakamura, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suzuki, C.
Right arrow Articles by Nakamura, Y.
[Cancer Research 63, 7038-7041, November 1, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Identification of COX17 as a Therapeutic Target for Non-Small Cell Lung Cancer1

Chie Suzuki, Yataro Daigo, Takefumi Kikuchi, Toyomasa Katagiri and Yusuke Nakamura2

Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan

We have been investigating gene expression profiles in non-small cell lung cancers (NSCLCs) to identify molecules involved in pulmonary carcinogenesis and select which genes or gene products might be useful as diagnostic markers or targets for new molecular therapies. Here we report evidence that the cytochrome c oxidase (CCO) assembly protein COX17 is a potential molecular target for treatment of lung cancers. By semiquantitative reverse transcription-PCR, we documented increased expression of COX17 in all of 8 primary NSCLCs and in 11 of 15 NSCLC cell lines examined, by comparison with normal lung tissue. Treatment of NSCLC cells with antisense S-oligonucleotides or vector-based small interfering RNAs of COX17 suppressed expression of COX17 and also the activity of CCO, and suppressed growth of the cancer cells. Because our data imply that up-regulation of COX17 function and increased CCO activity are frequent features of lung carcinogenesis, we suggest that selective suppression of components of the CCO complex might hold promise for development of a new strategy for treating lung cancers.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. Kato, N. Sato, A. Takano, M. Miyamoto, H. Nishimura, E. Tsuchiya, S. Kondo, Y. Nakamura, and Y. Daigo
Activation of Placenta-Specific Transcription Factor Distal-less Homeobox 5 Predicts Clinical Outcome in Primary Lung Cancer Patients
Clin. Cancer Res., April 15, 2008; 14(8): 2363 - 2370.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Ishikawa, A. Takano, W. Yasui, K. Inai, H. Nishimura, H. Ito, Y. Miyagi, H. Nakayama, M. Fujita, M. Hosokawa, et al.
Cancer-Testis Antigen Lymphocyte Antigen 6 Complex Locus K Is a Serologic Biomarker and a Therapeutic Target for Lung and Esophageal Carcinomas
Cancer Res., December 15, 2007; 67(24): 11601 - 11611.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Taniwaki, A. Takano, N. Ishikawa, W. Yasui, K. Inai, H. Nishimura, E. Tsuchiya, N. Kohno, Y. Nakamura, and Y. Daigo
Activation of KIF4A as a Prognostic Biomarker and Therapeutic Target for Lung Cancer
Clin. Cancer Res., November 15, 2007; 13(22): 6624 - 6631.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Hayama, Y. Daigo, T. Yamabuki, D. Hirata, T. Kato, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, and Y. Nakamura
Phosphorylation and Activation of Cell Division Cycle Associated 8 by Aurora Kinase B Plays a Significant Role in Human Lung Carcinogenesis
Cancer Res., May 1, 2007; 67(9): 4113 - 4122.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Yamabuki, A. Takano, S. Hayama, N. Ishikawa, T. Kato, M. Miyamoto, T. Ito, H. Ito, Y. Miyagi, H. Nakayama, et al.
Dikkopf-1 as a Novel Serologic and Prognostic Biomarker for Lung and Esophageal Carcinomas
Cancer Res., March 15, 2007; 67(6): 2517 - 2525.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. Suzuki, K. Takahashi, S. Hayama, N. Ishikawa, T. Kato, T. Ito, E. Tsuchiya, Y. Nakamura, and Y. Daigo
Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer
Mol. Cancer Ther., February 1, 2007; 6(2): 542 - 551.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Kato, S. Hayama, T. Yamabuki, N. Ishikawa, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, Y. Nakamura, and Y. Daigo
Increased Expression of Insulin-like Growth Factor-II Messenger RNA-Binding Protein 1 Is Associated with Tumor Progression in Patients with Lung Cancer
Clin. Cancer Res., January 15, 2007; 13(2): 434 - 442.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Hayama, Y. Daigo, T. Kato, N. Ishikawa, T. Yamabuki, M. Miyamoto, T. Ito, E. Tsuchiya, S. Kondo, and Y. Nakamura
Activation of CDCA1-KNTC2, Members of Centromere Protein Complex, Involved in Pulmonary Carcinogenesis
Cancer Res., November 1, 2006; 66(21): 10339 - 10348.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. P. Spugnini, I. Cardillo, A. Verdina, S. Crispi, S. Saviozzi, R. Calogero, A. Nebbioso, L. Altucci, G. Cortese, R. Galati, et al.
Piroxicam and Cisplatin in a mouse model of peritoneal mesothelioma.
Clin. Cancer Res., October 15, 2006; 12(20): 6133 - 6143.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Takahashi, C. Furukawa, A. Takano, N. Ishikawa, T. Kato, S. Hayama, C. Suzuki, W. Yasui, K. Inai, S. Sone, et al.
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
Cancer Res., October 1, 2006; 66(19): 9408 - 9419.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Suzuki, Y. Daigo, N. Ishikawa, T. Kato, S. Hayama, T. Ito, E. Tsuchiya, and Y. Nakamura
ANLN Plays a Critical Role in Human Lung Carcinogenesis through the Activation of RHOA and by Involvement in the Phosphoinositide 3-Kinase/AKT Pathway
Cancer Res., December 15, 2005; 65(24): 11314 - 11325.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Furukawa, Y. Daigo, N. Ishikawa, T. Kato, T. Ito, E. Tsuchiya, S. Sone, and Y. Nakamura
Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer
Cancer Res., August 15, 2005; 65(16): 7102 - 7110.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Kato, Y. Daigo, S. Hayama, N. Ishikawa, T. Yamabuki, T. Ito, M. Miyamoto, S. Kondo, and Y. Nakamura
A Novel Human tRNA-Dihydrouridine Synthase Involved in Pulmonary Carcinogenesis
Cancer Res., July 1, 2005; 65(13): 5638 - 5646.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T Nagahata, T Sato, A Tomura, M Onda, K Nishikawa, and M Emi
Identification of RAI3 as a therapeutic target for breast cancer
Endocr. Relat. Cancer, March 1, 2005; 12(1): 65 - 73.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Ishikawa, Y. Daigo, W. Yasui, K. Inai, H. Nishimura, E. Tsuchiya, N. Kohno, and Y. Nakamura
ADAM8 as a Novel Serological and Histochemical Marker for Lung Cancer
Clin. Cancer Res., December 15, 2004; 10(24): 8363 - 8370.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.